Author at Microdose

Elisabetta Fato

A native Italian, I currently study Biomedical Sciences at Queen Mary University of London. I have been closely following the latest updates in psychedelics research since the beginning of my undergraduate studies. My passion for science and writing allowed me to write articles published by the British Pharmacological Society and Neurosight, now available on their online magazine and blog respectively. In the future, I am determined to pursue a research career in Neuroscience and Neuropsychopharmacology for the study of Human Consciousness, and I truly believe in the potential of psychedelics as tools that could be used for the investigation of its nature.

Science

19 Jan 2023

New Study Shows Psilocybin Increases Music Pleasure in Depression Patients

New study showed a correlation between psilocybin treatments and increased level of music-evoked emotions in depression patients...

By Elisabetta Fato

Science

23 Nov 2022

New Study Shows Psychedelics Lowers Barriers to Higher Brain States

A recent study conducted by Cornell University has shown that psychedelics might lower the energy threshold brain networks require in order to shift to different configurations....

By Elisabetta Fato

Science

5 Oct 2022

New Study Shows Physical Healing Potential of Ayahuasca

A recent study showed the regenerative properties and wound healing of ayahuasca and were investigated in vitro....

By Elisabetta Fato

Industry, Science

7 Sep 2022

A Deeper Look at Ketamine for Alcohol Use Disorder

The psychedelic compound ketamine is gaining particular attention for the treatment of alcohol use disorder (AUD), with clinical studies being conducted to explore its potential....

By Elisabetta Fato

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

21 Jul 2022

Science Feature: MindMed’s LSD Trial for ADHD

We take a deeper look at MindMed’s phase 2a trial using low doses of LSD for ADHD...

By Elisabetta Fato

Science

14 Jul 2022

Science Feature: Next-Generation Psychedelics

Next-generation psychedelics are compounds whose structure derives or is built upon classical psychedelics like DMT, LSD and psilocybin — yet changed by inserting modifications to reduce possible adverse effects....

By Elisabetta Fato

Science

1 Jul 2022

Science Feature: Can Psychedelics Help Cure Color-Blindness?

In a 2017 online survey, psychedelic users reported improved symptoms of color-blindness....

By Elisabetta Fato

Science

24 Jun 2022

Science Feature: Psychedelics for Neuro-degenerative Diseases

Psychedelics are gradually catching on in mental health therapeutics and captivating more and more researchers, it seems their mechanism of action could be exploited in other therapeutic fields, such as...

By Elisabetta Fato

Science

14 Jun 2022

Science Feature: A Look at MDMA for PTSD

The legalization and destigmatization of psychedelics are being increasingly encouraged and supported, especially by the community of war veterans, with studies and personal reports of their therapeutic effects on PTSD...

By Elisabetta Fato

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

WordPress Ads